PubMed · 11367220
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
2000-01-21. Sergeant sentenced.. https://pubmed.ncbi.nlm.nih.gov/11367220/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Two longitudinal surveys were carried out in 1996 and 1999 aimed at describing the situations of AIDS-related discrimination in the workplace and evaluating the effectiveness of some social interventions against discrimination towards HIV-positive employees. Two hundred and ninety-nine and 212 companies completed a questionnaire in 1996 and 1999, respectively. The results are mixed. Although most of the sampled companies had no HIV/AIDS-related policy, their awareness of related legislation increased over the three-year period. Over the three-year study period, more companies indicated they would disclose information of their HIV-positive employees if known to the company; however, fewer companies indicated they would dismiss an employee because of his or her HIV-positive status. Only a few companies indicated that they would provide counselling and support to an HIV-positive employee.
Treatment of HCV infection in HIV seropositives is becoming a management priority because of: the increasing HCV and stage liver disease mortality and the unfavourable impact of HCV infection on efficacy and toxicity of antiretroviral combination treatment. Treatment end points are: eradication of HCV or suppression of HCV replication in order to slow HCV disease progression and to increase efficacy and to reduce hepatotoxicity of antiretrovirals. Interferon as monotherapy and in combination with ribavirin induces eradication of HCV in respectively 17 and 28% and suppression of viral replication in 26 and 36% of treated HIV infected subjects. The impact of these drugs on HIV disease evolution and on antiretroviral treatment efficacy, toxicity and compliance needs to be established. Then the cost-effectiveness of anti HCV therapy in anti HIV infected patients still needs to be defined.
In a voluntary anonymous HIV and hepatitis C serology screen in a Canadian male medium security federal penitentiary, 68% of 520 prisoners volunteered a blood sample and 99% of those giving a blood sample completed a risk behaviour questionnaire which was linked numerically to the blood sample. Compared to previous screenings for HIV (4 years earlier), and hepatitis C (3 years earlier) in the same institution, HIV seroprevalence had risen from 1% to 2% and hepatitis C seroprevalence from 28% to 33%. The overwhelming risk association for hepatitis C was with drug use outside prison, although there was a small group of men who had only ever injected drugs inside prison, over half of whom had been infected with hepatitis C. The proportion of prisoners who had injected drugs in prison rose from 12% in 1995 to 24% in 1998. The proportion of surveyed individuals sharing injection equipment at some time in prison was 19%, and while HIV rates in the prison are currently low, HIV prevalence amongst Canadian street i.v. drug users is rising rapidly, underlining the need for urgent preventative measures in prisons.